GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Valuation Rank

Jazz Pharmaceuticals (FRA:J7Z) Valuation Rank


View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Jazz Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Valuation Rank
Comparable Companies
CYTK EXEL PCVX IONS APLS ASND CERE RVMD BPMC VKTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
JAZZ:USA JAZZ:Mexico
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Website
https://www.jazzpharmaceuticals.com
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.